1 차 진료에서 비암 통증에 대한 장기 오피오이드 치료 환자의 치료 개선 (Opi-Prim)
1 차 진료에서 비암 통증에 대한 장기 오피오이드 요법 환자의 치료 개선 (OPI-PRIM)
The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:
What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?
Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.
Participants will receive a person-centred team-based treatment consisting of:
- Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
- Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
- Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.
Primary objective:
To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care
Trial design and setting:
This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).
This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.
Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Magnus Peterson, PhD, MD
- 전화번호: +46702882768
- 이메일: magnus.peterson@regionuppsala.se
연구 연락처 백업
- 이름: Anna Svensson, MD
- 전화번호: +46702206400
- 이메일: anna.k.svensson@uu.se
연구 장소
-
-
Gävleborg County
-
Gävle, Gävleborg County, 스웨덴
- 아직 모집하지 않음
- Region Gävleborg
-
연락하다:
- Paul Dranichnikov, MD, PhD
- 전화번호: +46762175118
- 이메일: paul.dranichnikov@uu.se
-
-
Södermanland County
-
Strängnäs, Södermanland County, 스웨덴
- 아직 모집하지 않음
- Region Sörmland
-
연락하다:
- Johanna Haraldsson, MD, PhD
- 전화번호: +46708636813
- 이메일: johanna.haraldsson@uu.se
-
-
Uppsala County
-
Uppsala, Uppsala County, 스웨덴
- 모병
- Region Uppsala
-
연락하다:
- Anna Svensson, MD
- 전화번호: +46702206400
- 이메일: anna.k.svensson@uu.se
-
-
Örebro County
-
Örebro, Örebro County, 스웨덴
- 모병
- Region Örebro Län
-
연락하다:
- Elsa Ekelin, MD
- 전화번호: +46708395260
- 이메일: elsa.ekelin@regionorebrolan.se
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
- Able to speak Swedish or English
Exclusion Criteria:
- Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
- No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
- Using their opioids for cancer pain
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
간섭 없음: Control
Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care. |
|
|
활성 비교기: Intervention
Phase 1 (investigation and assessment, week 1-3):
Phase 2 (treatment plan, week 3-4): - A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24):
|
Phase 1 (investigation and assessment, week 1-3):
Phase 2 (treatment plan, week 3-4): - A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24):
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pain interference
기간: The primary outcome measure will be the difference in mean pain interference after 6 months.
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse. |
The primary outcome measure will be the difference in mean pain interference after 6 months.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pain intensity
기간: After 3, 6 and 12 months
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse |
After 3, 6 and 12 months
|
|
Symptoms of depression
기간: After 3, 6 and 12 months
|
Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse |
After 3, 6 and 12 months
|
|
Symptoms of anxiety
기간: After 3, 6 and 12 months
|
Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse |
After 3, 6 and 12 months
|
|
Patient satisfaction
기간: After 3, 6 and 12 months
|
Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse |
After 3, 6 and 12 months
|
|
Quality of life according to the 5-level EuroQol 5D
기간: After 3, 6 and 12 months
|
Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse. |
After 3, 6 and 12 months
|
|
Opioid use
기간: After 3, 6 and 12 months
|
Measured with as morphine equivalents: in mg. |
After 3, 6 and 12 months
|
|
Symptoms of withdrawal
기간: After 3, 6 and 12 months
|
Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse |
After 3, 6 and 12 months
|
|
Pain interference
기간: After 3 and 12 months
|
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse. |
After 3 and 12 months
|
공동 작업자 및 조사자
협력자
협력자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- Opi-Prim
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .